Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/17930

Title: Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy
Authors: BOSETTI, Rita
Ferrandina, Gabriella
Scambia, Giovanni
Issue Date: 2014
Citation: NANOMEDICINE, 9 (14), p. 2175-2186
Abstract: This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer.
Notes: Bosetti, R (reprint author), Hasselt Univ, Dept Appl Econ, Martelarenlaan 42 BE3500, Hasselt, Belgium. rita.bosetti@uhasselt.be
URI: http://hdl.handle.net/1942/17930
Link to publication: http://www.ncbi.nlm.nih.gov/pubmed/25405795
DOI: 10.2217/nnm.14.150
ISI #: 000345285700010
ISSN: 1743-5889
Category: A1
Type: Journal Contribution
Validation: ecoom, 2015
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.